(Q33874286)

29 July 2017

Reversible tumorigenesis by MYC in hematopoietic lineages (English)

1 reference

29 July 2017

Felsher DW

1

1 reference

PubMed ID

10488335

29 July 2017

Bishop JM

series ordinal

2

1 reference

29 July 2017

1 August 1999

1 reference

29 July 2017

1 reference

29 July 2017

4

1 reference

29 July 2017

199-207

1 reference

29 July 2017

2

1 reference

The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice

29 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Suppression of human colorectal carcinoma cell growth by wild-type p53

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Molecular themes in oncogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Control of cell proliferation by Myc.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

MYC abrogates p53-mediated cell cycle arrest in N-(phosphonacetyl)-L-aspartate-treated cells, permitting CAD gene amplification

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

c-Myc target genes involved in cell growth, apoptosis, and metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Conditional transformation of a pancreatic beta-cell line derived from transgenic mice expressing a tetracycline-regulated oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Apoptosis and the cell cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Transient excess of MYC activity can elicit genomic instability and tumorigenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Tight control of gene expression in mammalian cells by tetracycline-responsive promoters

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Transcriptional activation by tetracyclines in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

The E mu-myc transgenic mouse. A model for high-incidence spontaneous lymphoma and leukemia of early B cells

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Cooperation between oncogenes

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Antisense strategies for the treatment of hematological malignancies and solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Non-Ras targets of farnesyltransferase inhibitors: focus on Rho.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Consequences of widespread deregulation of the c-myc gene in transgenic mice: multiple neoplasms and normal development

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Genetic instabilities in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

myc function and regulation

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Loss of oncogenic ras expression does not correlate with loss of tumorigenicity in human cells

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model.

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Doxycycline control of prion protein transgene expression modulates prion disease in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Single-photon emission computed tomography gallium imaging versus computed tomography: predictive value in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation for non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

BCL-2 antisense therapy in patients with non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

Strain dependency of B and T lymphoma development in immunoglobulin heavy chain enhancer (E mu)-myc transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1097-2765%2800%2980367-6

7 January 2021

10.1016/S1097-2765(00)80367-6

Identifiers

DOI

1 reference

29 July 2017

1 reference

PubMed ID

10488335